Sažetak
Uvod/Cilj: Hemolitička bolest novorođenčeta predstavlja hemoliznu anemiju koja se javlja kao posledica nepodudarnosti krvi roditelja, odnosno nepodudarnosti krvnih elemenata majke i ploda u ABO ili Rh sistemu. Cilj ovog rada je da prikaže slučaj hemolitičke bolesti novorođenčeta nastale kao posledica ABO inkompatibilije kod majke.
Prikaz bolesnika: Ženskom novorođenčetu je u osamnaestom satu života registrovana indirektna hiperbilirubinemija. Krvna grupa novorođenčeta je bila A Rh (D) pozitivna, direktni Coombs test bio je pozitivan, a u krvi novorođenčeta su detektovana anti-A antitela. Ovaj slučaj je uspešno lečen fototerapijom i transfuzijom resuspendovanih eritrocita bez potrebe za eksangvinotransfuzijom.
Zaključak: ABO inkompatibilija može predstavljati veliki problem kako u prenatalnom, tako i u perinatalnom i neonatalnom periodu. Posebnu pažnju treba obratiti na trudnice čija su deca iz prethodnih trudnoća imala hiperbilirubinemiju ili su im se trudnoće završavale spontanim pobačajem.
Ključne reči
Reference
1. Dufour DR, Monoghan WP. ABO hemolytic disease of the newborn. A retrospective analysis of 254 cases. Am J Clin Pathol 1980; 73(3):369-73. doi: 10.1093/ajcp/73.3.369.
2. Lazarus C, Avchen R. Neonatal hyperbilirubinemia management: a model for change. J Perinatol 2009; 29:S58–S60. doi: 10.1038/jp.2008.217
3. Kaur D, Sidana P, Mandhan G,Kanodia K. Oblivious of the Yellow World – A Newborn’s Telltale: ABO Hemolytic Disease of Newborn. Glob J Transfus Med 2019; 4(1):87-89. doi: 10.4103/GJTM.GJTM_45_18
4. Hall V, Avulakunta ID. Hemolytic diseases of the newborn. [Updated 2021 Aug 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK557423/
5. Trainor B, Tubman R. The emerging pattern of hydrops fetalis--incidence, aetiology and management. Ulster Med J 2006;75(3):185-186.
6. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114(1):297-316. doi: 10.1542/peds.114.1.297
7. Fasano RM. Hemolytic disease of the fetus and newborn in the molecular era. Semin Fetal Neonatal Med 2016;21(1):28-34. doi:10.1016/j.siny.2015.10.006
8. Chen JY, Ling UP. Prediction of the development of neonatal hyperbilirubinemia in ABO incompatibility. Zhonghua yi xue za zhi = Chinese Medical Journal; Free China ed. 1994; 53(1):13-18. PMID: 8173995.
9. Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2007;
92(2):F83-8. doi: 10.1136/adc.2005.076794.
10. Adewuyi JO, Gwanzura C. Racial difference between white and black Zimbabweans in the haemolytic activity of A, B, O antibodies. Afr J Med Med Sci 2001; 30(1-2):71- 74.
11. McDonncell M, Hannam S, Devane SP. Hydrops fetalis due to ABO incompatibility. Arch Dis Child Fetal Neonatal Ed 1998; 78(3):F220-221. doi: 10.1136/fn.78.3.f220
12. Malekasgar AM. ABO blood group prevalence in spontaneously repeated abortion. Turk J Haematol 2004; 21(4):181-7.
13. Stiller RJ, Herzlinger R, Siegel S, Whetham JC. Fetalascites associated with ABO incompatibility: case reportand review of the literature. Am J Obstet Gynecol 1996; 175: 1371-1372. doi: 10.1016/s0002-378(96)70057-1
14. Hyperbilirubinemia: Unconjugated. In: Gomella T, Eyal FG, Bany-Mohammed F. eds. Gomella's Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs, 8e. McGraw Hill; 2020. Available at: https://accesspediatrics.mhmedical.com/content.aspx?bookid=2762§ionid=234453147(cited June 11, 2022. )